002294 Shenzhen Salubris Pharmaceuticals
- 27.26
- -0.49-1.77%
Shenzhen Salubris Pharmaceuticals News
Salubris Pharmaceuticals Gets Nod to Market Hypertension Drug
Shenzhen Salubris Pharmaceuticals (SHE:002294) received a drug registration certificate from China's National Medical Products Administration for allisartan medoxomil amlodipine tablets, according to
A Look At The Fair Value Of Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294)
Key Insights Shenzhen Salubris Pharmaceuticals' estimated fair value is CN¥30.19 based on 2 Stage Free Cash Flow to Equity Shenzhen Salubris Pharmaceuticals' CN¥28.70 share price indicates it is tra
Xinlitai (002294.SZ): Shareholder Runfu plans to donate 2 million shares free of charge to Ye Chenghai Charity Foundation
Gelonghui, May 13 | Xinlitai (002294.SZ) announced that the company recently received a “Notice Letter on Free Donation of Part of the Shares” from shareholder Shenzhen Runfu Investment and Development Co., Ltd. (hereinafter referred to as “Runfu”). It plans to donate 2 million shares (0.18% of the company's total share capital) held free of charge to Shenzhen Ye Chenghai Charity Foundation (hereinafter referred to as the “Foundation”). All proceeds from the sale of shares of the Foundation will be used to donate funds to public welfare undertakings such as financial aid. Among them, a targeted donation of not less than 50 million yuan will be made to Shenzhen University, and the remaining amount will be used for the Foundation to develop charity
Shenzhen Salubris Pharmaceuticals Co., Ltd.'s (SZSE:002294) On An Uptrend But Financial Prospects Look Pretty Weak: Is The Stock Overpriced?
Shenzhen Salubris Pharmaceuticals' (SZSE:002294) stock is up by a considerable 18% over the past three months. We, however wanted to have a closer look at its key financial indicators as the markets
Salubris Pharmaceuticals to Raise Capital of US Unit by $35 Million
Shenzhen Salubris Pharmaceuticals (SHE:002294) will inject an additional $35 million into the capital of its US unit, Salubris Biotherapeutics, the company said in its filing on the Shenzhen Stock Exc
Xinlitai (002294.SZ) plans to increase Salubris Bio's capital with self-financing of 35 million US dollars
Xinlitai (002294.SZ) announced that Salubris Biotherapeuti...
Xinlitai (002294.SZ): Net profit of 200 million yuan in the first quarter decreased by 5.06% year-on-year
Gelonghui, April 22 | Xinlitai (002294.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 1,091 billion yuan, up 22.92% year on year; net profit attributable to shareholders of listed companies was 200 million yuan, down 5.06% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 201 million yuan, up 4.50% year on year; basic earnings per share were 0.180 yuan.
Shenzhen Xintai Pharmaceutical's Drug to Treat Chronic Heart Failure Set for Clinical Trials
Shenzhen Xintai Pharmaceutical (SHE:002294) and Salubris Biotherapeutics received approval from the National Medical Products Administration (NMPA) to carry out a Phase II clinical trial for their hea
Xinlitai (002294.SZ): JK07 injection approved to conduct phase II clinical trials to treat chronic heart failure in adults
Xinlitai (002294.SZ) announced that the company, Salubris Biotherape of the United States...
Pinning Down Shenzhen Salubris Pharmaceuticals Co., Ltd.'s (SZSE:002294) P/E Is Difficult Right Now
With a price-to-earnings (or "P/E") ratio of 55x Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) may be sending very bearish signals at the moment, given that almost half of all companies in
Shanghai Securities: A new mechanism for oral antihypertensive drugs has been approved by the FDA for marketing, and attention is being paid to the cardiovascular drug circuit
The Zhitong Finance App learned that Shanghai Securities released a research report saying that on March 19, the US FDA announced approval for the launch of Tryvio, a new molecular physical drug developed by Idorsia. Tryvio is an endothelin receptor antagonist used to treat high blood pressure that is still insufficiently controlled when combined with other antihypertensive drugs. Notably, Tryvio is the first oral antihypertensive therapy approved to work through a new treatment route in nearly 30 years. According to the “China Cardiovascular Health and Disease Report 2022”, the prevalence of cardiovascular disease in China continues to rise. The current number of patients is estimated to be 330 million.
Salubris Pharma's Profit, Revenue Slip in 2023
Shenzhen Salubris Pharmaceuticals (SHE:002294) recorded a profit attributable to shareholders of 580.1 million yuan in 2023, slipping 9% from 637.1 million yuan a year ago, according to the company's
These 4 Measures Indicate That Shenzhen Salubris Pharmaceuticals (SZSE:002294) Is Using Debt Safely
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Southwest Securities: There is still a lot of room for penetration in the coronary artery disease interventional treatment market, focus on Sano Healthcare (688108.SH), etc.
Coronary heart disease is the leading cause of death in the world, and there is still plenty of room for penetration in the interventional treatment market for coronary artery disease in China.
Optimism for Shenzhen Salubris Pharmaceuticals (SZSE:002294) Has Grown This Past Week, Despite Five-year Decline in Earnings
When we invest, we're generally looking for stocks that outperform the market average. And while active stock picking involves risks (and requires diversification) it can also provide excess returns.
Is Shenzhen Salubris Pharmaceuticals Co., Ltd.'s (SZSE:002294) Stock On A Downtrend As A Result Of Its Poor Financials?
Shenzhen Salubris Pharmaceuticals (SZSE:002294) has had a rough month with its share price down 6.1%. We decided to study the company's financials to determine if the downtrend will continue as the
Xinlitai (002294.SZ): Shareholder Runfu plans to donate 0.45% of his shares to Beijing Renmin University Education Foundation free of charge
Gelonghui, January 15, 丨 Xinlitai (002294.SZ) announced that the company recently received a notice from its shareholder Shenzhen Runfu Investment and Development Co., Ltd., that in order to support the development of educational undertakings such as talent training, teaching and research at Renmin University of China, its plan is to donate 5 million shares (0.45% of the company's total share capital) with unlimited sales conditions to the Beijing Renmin University of China Education Foundation through non-transactional transfers, mainly for the preparation and operation of the Higher Institute for Global Development and Safety in schools. As of the disclosure date of this announcement, Runfu held 22,465,952 shares of the company, accounting for
Xinlitai (002294.SZ): It is proposed to launch the third phase of the employee stock ownership plan to raise a total of 614 million yuan
On December 22, Gelonghui (002294.SZ) announced the third phase of the employee stock ownership plan (draft). The total amount of capital to be raised in this phase of the employee stock ownership plan is 614 million yuan. The final total amount of capital raised is based on the actual total capital raised. The participants in this phase of the employee stock ownership plan are company directors (excluding independent directors), supervisors, senior management, and other core and key employees. The total number of participants in this phase of the employee stock ownership plan is expected to be no more than 300. The exact number of participants is determined according to actual payment conditions. The current employee stock ownership plan lasts no more than 48 months, after consideration and approval by the shareholders' meeting
Some Xinlitai (002294.SZ) drugs are included in the national medical insurance catalogue
Xinlitai (002294.SZ) announcement, according to the “On India...” issued by the National Health Insurance Administration and the Ministry of Human Resources and Social Security
Xinlitai (002294.SZ): arisartan ester tablets (xinalotan) and enaldostat tablets (ennarol) are included in the national medical insurance catalogue
<国家基本医疗保险、工伤保险和生育保险药品目录 (2023年) >Gelonghui (002294.SZ) announced on December 13|Xinlitai (002294.SZ) announced that according to the “Notice on Issuance” (Health Insurance Development [2023] No. 30) issued by the National Health Insurance Administration and the Ministry of Human Resources and Social Security, the innovative drug xinritan (generic name: alisartan ester tablets, with specifications of 80 mg/tablets and 240 mg/tablets, respectively) passed negotiations and was included in the national basic medical insurance, work injury insurance and maternity insurance drug catalogue (2023) Year) (hereinafter referred to as the “Medical Insurance Catalogue”
Analysis
Price Target
No Data
